2016
Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue
Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood 2016, 128: 1188. DOI: 10.1182/blood.v128.22.1188.1188.Peer-Reviewed Original ResearchAutologous stem cell transplantationReconstructed individual patient dataIncremental cost-effectiveness ratioR Hodgkin lymphomaIndividual patient dataHodgkin's lymphomaActive surveillanceOverall survivalHealth care costsHL progressionHL recurrenceHealthcare costsCare costsHigh-risk Hodgkin lymphomaSignificant health care costsDouble-blind trialPatient dataUse of BVFirst-line therapyHigh-dose chemotherapyPrimary refractory diseaseProgression-free survivalStem cell rescueLong-term followStem cell transplantation
2012
New health conditions identified at a regional childhood cancer survivor clinic visit
Hogan M, Ma X, Kadan‐Lottick N. New health conditions identified at a regional childhood cancer survivor clinic visit. Pediatric Blood & Cancer 2012, 60: 682-687. PMID: 23023769, DOI: 10.1002/pbc.24360.Peer-Reviewed Original ResearchConceptsNew health conditionsClinic visitsSurvivorship clinicChildhood cancerHealth conditionsOdds ratioChildren's Oncology Group Long-Term FollowCancer treatment exposuresRegular medical careCancer diagnosisPotential treatment-related effectsLong-term followCancer survivorship clinicTherapy-related effectsTreatment-related effectsRisk-based screeningGroup of survivorsSurvivor clinicChest irradiationPulmonary dysfunctionSubsequent cancerLate complicationsNeurologic impairmentAssociated FactorsMultivariate regression model